长三角AI生物医药产业联盟在江苏无锡成立

Core Viewpoint - The establishment of the Yangtze River Delta AI Biomedicine Industry Alliance marks a significant step in exploring the integration of AI and biomedicine in the region [1][3]. Group 1: Alliance Formation - The alliance is led by the Wuxi Biomedicine Industry Association and involves institutions like Peking University and AstraZeneca, with 40 forward-looking AI medical companies joining as founding members [3]. - The core philosophy of the alliance is "innovation-driven, collaborative empowerment, and value sharing," aiming to integrate resources from government, hospitals, universities, pharmaceutical companies, and AI biomedicine enterprises [3]. Group 2: Functional Focus - The alliance will focus on the core needs of AI drug development and will perform five key functions: technology exchange, industry connection, policy empowerment, financial support, and brand building [3][4]. - It aims to facilitate deep penetration and innovative application of AI technology across the entire chain of biomedicine research, production, and application [3]. Group 3: Support for Member Companies - Member companies will benefit from a cross-border cooperation platform that provides diverse resource support from clinical, academic, and commercial sectors [4]. - The alliance will regularly organize AI technology training, publish industry white papers, and host international academic exchange activities to enhance the technical competitiveness of member companies [4]. Group 4: Conference Highlights - The 2025 Taihu Bay Life Health Future Conference focuses on themes such as "AI empowering pharmaceutical innovation" and aims to create a one-stop ecological cooperation platform for research, production, sales, and finance [5]. - New innovation centers and policies to support the biomedicine industry in Wuxi were unveiled during the conference, injecting new momentum into local biomedicine innovation [5].